These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 12577791)

  • 1. [Prolonging the QT time with drugs].
    Wilde AA; Pfaffendorf M
    Med Monatsschr Pharm; 2003 Jan; 26(1):4-10; quiz 11-2. PubMed ID: 12577791
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-induced torsades de pointes--a form of mechano-electric feedback?
    Fabritz L
    Cardiovasc Res; 2007 Nov; 76(2):202-3. PubMed ID: 17869232
    [No Abstract]   [Full Text] [Related]  

  • 3. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts.
    Wu L; Shryock JC; Song Y; Belardinelli L
    J Pharmacol Exp Ther; 2006 Feb; 316(2):718-26. PubMed ID: 16234410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of high-risk use of QT-prolonging medications.
    Allen LaPointe NM; Curtis LH; Chan KA; Kramer JM; Lafata JE; Gurwitz JH; Raebel MA; Platt R
    Pharmacoepidemiol Drug Saf; 2006 Jun; 15(6):361-8. PubMed ID: 16178046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines.
    Arbel Y; Swartzon M; Justo D
    Anticancer Drugs; 2007 Apr; 18(4):493-8. PubMed ID: 17351403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study.
    Hinterseer M; Thomsen MB; Beckmann BM; Pfeufer A; Schimpf R; Wichmann HE; Steinbeck G; Vos MA; Kaab S
    Eur Heart J; 2008 Jan; 29(2):185-90. PubMed ID: 18156612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening drugs for QT prolongation.
    Somberg J
    Am J Ther; 2007; 14(5):419-20. PubMed ID: 17890927
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-induced long QT and torsade de pointes: recent advances.
    Kannankeril PJ; Roden DM
    Curr Opin Cardiol; 2007 Jan; 22(1):39-43. PubMed ID: 17143043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketoconazole induced torsades de pointes without concomitant use of QT interval-prolonging drug.
    Mok NS; Lo YK; Tsui PT; Lam CW
    J Cardiovasc Electrophysiol; 2005 Dec; 16(12):1375-7. PubMed ID: 16403073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Famotidine and long QT syndrome.
    Lee KW; Kayser SR; Hongo RH; Tseng ZH; Scheinman MM
    Am J Cardiol; 2004 May; 93(10):1325-7. PubMed ID: 15135720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac effects of desipramine.
    Waslick B
    J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):125-6. PubMed ID: 7534755
    [No Abstract]   [Full Text] [Related]  

  • 13. Long QT syndrome caused by noncardiac drugs.
    Viskin S; Justo D; Halkin A; Zeltser D
    Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Proarrhythmic (torsadogenic) effects of QT-prolonging non-antiarrhythmic drugs].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Mar; 146(10):451-60. PubMed ID: 15835343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QT prolongation in guinea pigs for preliminary screening of torsadogenicity of drugs and drug-candidates. II.
    Testai L; Breschi MC; Martinotti E; Calderone V
    J Appl Toxicol; 2007; 27(3):270-5. PubMed ID: 17265420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propofol reduces idiopathic prolonged QT interval and QT dispersion during implantation of cardioverter defibrillator.
    Michaloudis D; Kanoupakis E
    Anesth Analg; 2003 Jul; 97(1):301-2; author reply 302. PubMed ID: 12818999
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced long QT syndrome and Torsade de Pointes.
    Chism S; Smith E
    J Ark Med Soc; 2004 Jul; 101(1):24-6. PubMed ID: 15270138
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-induced torsades de pointes in patients aged 80 years or more.
    Paran Y; Mashav N; Henis O; Swartzon M; Arbel Y; Justo D
    Anadolu Kardiyol Derg; 2008 Aug; 8(4):260-5. PubMed ID: 18676301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecularly targeted oncology therapeutics and prolongation of the QT interval.
    Strevel EL; Ing DJ; Siu LL
    J Clin Oncol; 2007 Aug; 25(22):3362-71. PubMed ID: 17664484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.